FindTrial
Sign In

The antitumor activity of ametinib in preclinical NSCLC models harboring the uncommon EGFR mutations

The antitumor activity of ametinib in preclinical NSCLC models harboring the uncommon EGFR mutations

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100046744
Enrollment
Unknown
Registered
2021-05-28
Start date
2021-06-16
Completion date
Unknown
Last updated
2022-01-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cancer

Interventions

case series:Null

Sponsors

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18-75 years; 2. It is diagnosed as NSCLC by histopathology, and expresses any rare EGFR mutation such as 20 insert, G719X, L861Q, S768I or L747S; 3. There is malignant pleural effusion, and pleural effusion is needed for treatment; 4. The subject voluntarily participated and signed the informed consent form in writing.

Exclusion criteria

Exclusion criteria: Not suitable for the treatment of pleural effusion.

Design outcomes

Primary

MeasureTime frame
Inhibition of tumor cell proliferation IC50;Inhibition of phosphorylation of EGFR and downstream signal factors;—

Countries

China

Contacts

Public ContactZhang Yu

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

11417560@qq.com+86 13971292838

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026